Back to Journal

Journal of Surgical Oncology & Clinical Research

Late-Onset Anaphylactic Reaction Induced by Patent Blue V During Sentinel Lymph Node Biopsy: A Rare Case Report and Brief Literature Review

[ ISSN : 3068-0727 ]

Abstract Abstract Citation INTRODUCTION MATERIALS, SUBJECTS AND METHODS CASE REPORT DISCUSSION PATIENT’S CONSENTE HUMAN SUBJECTS REFERENCES
Details

Received: 18-Sep-2025

Accepted: 30-Dec-2025

Published: 01-Jan-2026

Gabriela Conceição Gomes1*, Talita Giuzio¹, Amanda Vicentin Maruya¹, Carlos Alberto Menossi¹, Alice Cunha Lee² and Giovanna Da Conceição Gomes³

1Department of Mastology, Pontifical Catholic University of Campinas (PUC-Campinas), Brazil.

2Department of Anesthesiology, Pontifical Catholic University of Campinas (PUC-Campinas), Brazil.

3Institute of Collective Health - Federal University of Bahia (ISC-UFBA), Brazil.

Corresponding Author:

Gabriela Conceição Gomes, Department Of Mastology, Pontifical Catholic University of Campinas (PUC-Campinas), Campinas, São Paulo, Brazil

Keywords

Patent Blue V; Anaphylaxis; Sentinel lymph node; Breast cancer.

Abstract

Introduction: Patent Blue V is widely used for sentinel lymph node identification in breast cancer surgery but may cause severe adverse reactions such as anaphylaxis. Although rare, it represents a potentially life-threatening event requiring prompt recognition and management. Methods: A narrative literature review was conducted using PubMed, SciELO, and DOAJ databases, including articles and case reports published between 2005 and 2024 addressing allergic reactions to Patent Blue V. Case Report: A 70-year-old female patient with luminal A invasive carcinoma underwent a segmental mastectomy and sentinel lymph node biopsy (SLNB) after subdermal injection of 2 mL of 2.5% Patent Blue V. In the immediate postoperative period, she developed bluish urticaria, lip edema, and dyspnea without hemodynamic instability. The event was classified as grade II anaphylaxis (Ring and Messmer) and treated with intravenous epinephrine, diphenhydramine, and inhaled salbutamol, with complete resolution within a few hours. Discussion: Anaphylaxis induced by Patent Blue V may occur through immunological mechanisms (IgE-dependent or independent) or direct mast cell activation. Diagnosis is clinical, and prophylaxis remains unvalidated. Systematic reviews suggest a lower risk when using intradermal administration and dye volumes below 2 mL.

Abstract

Introduction: Patent Blue V is widely used for sentinel lymph node identification in breast cancer surgery but may cause severe adverse reactions such as anaphylaxis. Although rare, it represents a potentially life-threatening event requiring prompt recognition and management. Methods: A narrative literature review was conducted using PubMed, SciELO, and DOAJ databases, including articles and case reports published between 2005 and 2024 addressing allergic reactions to Patent Blue V. Case Report: A 70-year-old female patient with luminal A invasive carcinoma underwent a segmental mastectomy and sentinel lymph node biopsy (SLNB) after subdermal injection of 2 mL of 2.5% Patent Blue V. In the immediate postoperative period, she developed bluish urticaria, lip edema, and dyspnea without hemodynamic instability. The event was classified as grade II anaphylaxis (Ring and Messmer) and treated with intravenous epinephrine, diphenhydramine, and inhaled salbutamol, with complete resolution within a few hours. Discussion: Anaphylaxis induced by Patent Blue V may occur through immunological mechanisms (IgE-dependent or independent) or direct mast cell activation. Diagnosis is clinical, and prophylaxis remains unvalidated. Systematic reviews suggest a lower risk when using intradermal administration and dye volumes below 2 mL. Conclusion: Patent Blue V-induced anaphylaxis is rare but potentially severe. This case underscores the importance of continuous anesthetic and surgical vigilance and preparedness for immediate intervention. Keywords: Patent Blue V; Anaphylaxis; Sentinel lymph node; Breast cancer.

Citation

Gomes GC, Giuzio T, Maruya AV, Menossi CA, Cunha Lee CA, et al. (2026) Analysis of Medication Status of Subjects in Oral Anticancer Drug Clinical Trials and Discussion on Countermeasures. J Surg Oncol Clin Res. 2026; 5(1): 1014.

INTRODUCTION

With the advancement of oncologic treatment, sentinel lymph node biopsy (SLNB) has become the standard procedure for surgical staging of early invasive breast cancer [1]. Identification of the sentinel lymph node can be achieved using either Patent Blue V dye or the technetium based radiotracer, applied separately or in combination. The combination of both methods yields a sensitivity of approximately 98% for sentinel node detection [2]. However, Patent Blue V is associated with IgE mediated hypersensitivity reactions, which may be severe and require hemodynamic support. These manifestations range from mild cutaneous reactions to anaphylaxis with significant cardiovascular compromise. With an estimated incidence between 1:350 and 1:20,000—more recent studies narrowing this to one case per 1,000 to 10,000 procedures [3]-it remains a rare adverse reaction but one that warrants particular attention due to its potential clinical impact, necessitating early recognition and prompt management.

MATERIALS, SUBJECTS AND METHODS

To conduct this literature review on complications associated with the use of Patent Blue V, review articles and case reports addressing the topic were analyzed. The research was carried out in the DOAJ, PubMed, and SciELO databases. The following keywords were used: reaction; anaphylaxis; sentinel; Patent Blue — to identify articles published between 2004 and 2024 that aligned with the objectives of this review. Inclusion criteria comprised studies addressing allergic reactions to Patent Blue V, published between 2004 and 2024, in English or Portuguese. Articles that did not directly discuss the use of the dye or presented inconclusive data were excluded.

CASE REPORT

A 70-year-old female patient was diagnosed with invasive carcinoma of no special type, luminal A subtype (cT1 cN0 cM0). She underwent upfront surgery consisting of a left breast segmentectomy guided by ultrasound and ipsilateral sentinel lymph node biopsy (SLNB). Balanced general anesthesia was performed with intravenous administration of midazolam 2 mg, fentanyl 200 mcg, lidocaine 50 mg, propofol 70 mg, and rocuronium 30 mg. Hydrocortisone 500 mg was administered prophylactically prior to the use of Patent Blue V. Before the surgical incision, 2 mL of 2.5% Patent Blue V was injected into the periareolar subdermal tissue. The SLNB specimen was sent for intraoperative frozen section analysis, which revealed three lymph nodes free of malignancy. The procedure was uneventful, lasting a total of two hours.After extubation, the patient developed upper lip edema and bluish urticarial plaques (Figures 1 and 2), accompanied by pruritus and decreased vesicular breath sounds on auscultation, while maintaining hemodynamic stability. Approximately fifteen minutes later, she developed dyspnea and worsening pruritus. The anesthesia team promptly intervened, administering intravenous epinephrine (25 mcg), diphenhydramine 50 mg IV, and salbutamol (4 puffs), resulting in improvement of respiratory pattern and regression of the lesions. The patient remained under observation in the post-anesthesia care unit (PACU) with intravenous hydration and maintained hemodynamic stability without further complications. After two hours, no cutaneous alterations were observed, and she was discharged home the following day.

Figure 1 Personal Archive – Anterior view showing diffuse maculopapular skin eruptions with bluish discoloration

Figure 2: Personal Archive – Lateral view showing diffuse maculopapular skin eruptions with bluish discoloration.

DISCUSSION

After intradermal or intraparenchymal administration, Patent Blue is rapidly absorbed by the lymphatic vessels in the drainage area, where it binds to plasma albumin. Approximately two-thirds of the substance are absorbed within the first hour, with complete elimination occurring within 24 hours. Excretion takes place mainly through urine and bile [4]. Anaphylactic reactions related to Patent Blue are mediated by both immunologic and non-immunologic mechanisms. Immunologic reactions may involve IgE-dependent or IgE-independent pathways, whereas non immunologic reactions result from direct mast cell activation. Regardless of the underlying mechanism, the clinical presentation results from mast cell and basophil degranulation, leading to the release of mediators such as histamine, tryptase, platelet-activating factor (PAF), and cysteinyl leukotrienes [5]. The first sign of dye-induced anaphylaxis is often a progressive drop in oxygen saturation, which may or may not be accompanied by cutaneous manifestations and arterial hypotension. Treatment must be initiated immediately, including administration of 100% oxygen, vigorous fluid resuscitation, and the use of corticosteroids and antihistamines. In severe cases, epinephrine administration is essential for reversal. Diagnostic confirmation can be challenging, as available skin and serologic tests have limited sensitivity, and no validated preoperative prophylaxis protocols currently exist [2]. The incidence of severe adverse reactions to blue dyes (Patent Blue, Isosulfan Blue, Methylene Blue, and Indigo Carmine) used in sentinel lymph node biopsy for breast cancer and in melanoma surgery is low. Studies have shown that the risk of anaphylaxis is significantly lower in melanoma surgeries compared to breast surgeries. Furthermore, the use of smaller dye volumes (<2 mL) and intradermal administration are associated with reduced rates of anaphylactic reactions [6]. Although rare, adverse reactions to Patent Blue represent a potentially life-threatening complication for which no predictive tools or effective prophylactic measures currently exist. Therefore, surgical and anesthetic teams must maintain a high level of vigilance and readiness for immediate intervention. This case underscores the importance of continuous perioperative assessment and post-extubation monitoring, particularly when using substances with known allergenic potential. The patient presented with acute cutaneous and respiratory symptoms following Patent Blue exposure, meeting the diagnostic criteria for anaphylaxis as defined by the NIAID/FAAN (National Institute of Allergy and Infectious Diseases/ Food Allergy and Anaphylaxis Network). The reaction was classified as Grade II anaphylaxis according to the Ring and Messmer scale—without hemodynamic instability but requiring pharmacologic intervention with epinephrine, antihistamines, and bronchodilators. The delayed onset of anaphylaxis highlights the importance of post-anesthesia care unit (PACU) monitoring protocols to ensure early detection and management of emerging symptoms, emphasizing the need for team preparedness even when prophylaxis is used [7,8]. Finally, the current trend toward surgical de-escalation in axillary management—with ongoing multicenter trials evaluating the possibility of omitting sentinel lymph node biopsy—may, in the future, reduce the use of Patent Blue and consequently decrease the incidence of associated complications.

PATIENT’S CONSENTE

Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.

HUMAN SUBJECTS

Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements. The paper has been sufficiently anonymized to keep patient’s confidentiality.

REFERENCES

  1. Lombardi W, Semensato GR, Lombardi LB, Polizelli AP, Borges BLM, Caserta AA, et al. Reação alérgica ao azul patente: um raro relato de caso. Brazilian J Health Rev. 2024; 7: e67891.
  2. Shinzato JY, Marcaccini ACP, Braga A de F de A, Ribeiro AR, Rubio JEM, Souza JD de. Reação anafilática ao corante azul patente durante a biópsia do linfonodo sentinela em câncer de mama inicial: relato de caso. Revista Brasileira De Ginecologia E Obstetrícia. 2006; 28: 728-732.
  3. Pouessel G, Tacquard C, Tanno LK, Mertes PM, Lezmi G. Anaphylaxis mortality in the perioperative setting: Epidemiology, elicitors, risk factors and knowledge gaps. Clin Exp Allergy. 2024; 54: 11-20.
  4. Maranhão MVM, Nóbrega DKAD, Anunciação CEC, Maia BDAB, Mariano PVD. Reação alérgica ao corante azul patente em cirurgia de mama: relato de caso. Revista Brasileira de Anestesiologia. 2016; 66: 433-436.
  5. Solé D, Spindola MAC, Aun MV, Araújo Azi LMT, Bernd LAG, Garcia DB, et al. Atualização sobre reações de hipersensibilidade perioperatória: documento conjunto da Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira de Alergia e Imunologia (ASBAI) – Parte II: etiologia e diagnóstico. Braz J Anesthesiol. 2020; 70: 642-661.
  6. Perenyei M, Barber ZE, Gibson J, Hemington-Gorse S, Dobbs TD. Anaphylactic Reaction Rates to Blue Dyes Used for Sentinel Lymph Node Mapping: Systematic Review and Meta-analysis. Ann Surg. 2021; 273: 1087-1093.
  7. Harper NJN, Cook TM, Garcez T, Farmer L, Floss K, Marinho S. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaesth. 2018; 121: 159- 171.
  8. Walker DS, Jones RB, De Oliveira GS. Anaphylactic reaction rates to blue dyes used for sentinel lymph node mapping: a systematic review and meta-analysis. Ann Surg. 2021; 273: 1006-1012.

Citation

Gomes GC, Giuzio T, Maruya AV, Menossi CA, Cunha Lee CA, et al. (2026) Analysis of Medication Status of Subjects in Oral Anticancer Drug Clinical Trials and Discussion on Countermeasures. J Surg Oncol Clin Res. 2026; 5(1): 1014.

Other Articles

Article Image 1

Merkel Cell Carcinoma of the Inguinal Lymph Node in the Absence of a Primary Site: A New Case Report and Literature Review

Introduction: Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. The main characteristics are frequent local recurrences and disseminations to regional lymph nodes and distant organs. MCC within the lymph nodes in the absence of a primary site is rare and few cases have been reported by the literature.

Case Report: We report a case of MCC presenting as a painless mass in the left inguinal area for 6 months in a 48-year-old women. The histopathology of the excised lesion revealed a poorly differentiated basophilic small cell tumor. The immunohistochemical study finding the diagnosis of a metastatic MCC. Despite extensive clinical and radiological investigation, we failed to identify the origin of the tumor.

Conclusion: Rare cases of MCC confined to a lymph node without an apparent primary site have been reported. We report a new case of MCC in the inguinal lymph node without identification of the primary site.

Mohamed Amine Azami¹, Othman Lahbali¹, Iliass El Alami², Zouidia F¹, and Mahassini N¹*


Article Image 1

Can be Seroma a normal event in Breast Surgery? Analysis from Survey in Plastic Surgery Safety Conference

Introduction: Breast Surgery especially augmentation is a common procedure worldwide. Literature reports relationship between chronic seroma and Anaplastic Large Cell Lymphoma (ALCL) has increased. Recently we reported the first case in Mexico. Risk factors should be evaluated. Seroma seems to be a common event after this type of surgery. Chronic seroma seems to be most common symptom in ALCL

Methods: Survey was conducted during Security Conference in breast implant augmentation, to know features as breast implants ratio in private practice of plastic surgeons, type of implant used, surgical technique and complications. Descriptive statistics including measures of central tendency were estimated.

Results: 72 members answered the survey. Implant placement is a procedure performed frequently. Preference is textured implants with volume between 300cc and 360cc. The most common complication was seroma. Reoperation was related with capsular contracture and patient no satisfaction.

Discussion: Seroma is a common complication. Possible relation with biofilm and Anaplastic Large Cell Lymphoma should be evaluated. Lymphoma is not a common finding in breast implant but long lasting infection can be considered as risk factor. Measures to prevent seroma should be proposed. Analysis from the type of textured in the coverage of the implant should be evaluated.

Conclusion: This information allows us to take further action to direct sessions, courses and conferences, to decrease the frequency of seroma and prevent complications being one of the procedures most frequently performed by the membership.

Guillermo Ramos-Gallardo¹,², Carlos-Guillermo Oaxaca-Escobar¹, Jesus Cuenca Pardo¹, Livia Contreras-Bulnes¹, Eugenio Rodríguez-Olivares³, Imelda Díaz-Ruiz⁴, and Mauricio Alejandro García-López⁴*


Article Image 1

Percentage of Surgical Lung Cancers Missed by National Screening Criteria

Background: The US Preventive Services Task Force (USPSTF) recommends screening for smokers based on age, pack-years of smoking, and years since past smokers quit (quit-time). Previous studies determined low dose computerized tomography (LDCT) to be the best method, but have not identified the population at highest risk. This study sought the percentage of lung cancer patients that would have been excluded by USPSTF criteria.

Method: A retrospective chart review identified 170past and present smokers who had undergone lung cancer resection at Hackensack Meridian Health (HMH) hospitals between September 15, 2014 and 2016. Data was collected from the Society of Thoracic Surgeons database. Descriptive statistics and Wilcoxon Rank-Sum tests were used to analyze differences between included and excluded patients.

Results: The percentage of patients that would have been excluded by screening criteria was 46.5% (95% CI: 38.8-54.3%). The difference between ages of included and excluded patients was not quite significant (p=0.051), with only17.1% (95% CI: 11.7-23.6%) of all patients excluded by age. Pack-years of included patients were significantly higher than of the excluded (p<0.001), and 25.3% (95% CI: 18.9-32.6%) had insufficient pack years. Quit-time was also a significant variable (p<0.001) and excluded 37.9% (95% CI: 29.1-49.4%) of past smokers. The percentage included by USPSTF criteria increased from 53.5% to 59.4% when quit-time was set to 25 years, and61.2% when extended to 30 years.

Conclusion: USPSTF criteria would have excluded almost half of the ever-smokers with surgically resectable lung cancers. Age would not have excluded a significant percentage, but inclusion criteria should account for smokers with less than 30 pack-years or who quit over 15 years ago. Future reviews should examine screening efficacy in larger databases. Prospective studies should investigate correlation between age and smoking history, and look to include secondhand smoking and occupational exposure as risk factors for screening.

Hannah A Lee¹, Asa Dewan MS², Kelly Rubino BSN³, Mila Lachica BA¹,², Arthur A Topilow⁴ and Thomas L Bauer³*


Article Image 1

Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors

Thyroglobulin levels ≥50 μg/L following thyroidectomy and I131 ablation correlate with poor prognosis in patients with high risk Differentiated Thyroid Cancer (DTC). We describe a case of a 54 year old woman with differentiated thyroid cancer and high thyroglobulin up to 220 μg/L following thyroidectomy and I131 ablation who demonstrated marked response to a novel immunotherapy involving autologous tumor cell transfected with a GMCSF/bi-shRNA furin expressive plasmid (Vigil). Activity is highlighted by four year disease free survival in correlation with immune activation as measured by ELISPOT assay of peripheral blood mononuclear cell reaction to autologous tumor. Further investigation with Vigil in differentiated thyroid cancer is warranted.

Minal Barve¹,², Radhika Barve¹, Jennifer Rao¹, Luisa Manning³, Donald D Rao⁴, Ned Adams¹, Neil Senzer¹,³,⁴ and John Nemunaitis¹-⁵*



Article Image 1

Role of Pre -Treatment FDG PET Quantitative Parameters in Prognostication of Head and Neck Squamous Cell Carcinoma - A Review

In spite of the good organ preservation strategies available for locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC), failure rates have been reported to be as high as 35-50%. There has been an increasing interest in predicting response to treatment, to aid early intervention and better outcomes. FDG-PET is a standard modality for post treatment evaluation, however it is still under utilized as a pre-treatment investigative modality. Several articles have described quantitative parameters in pre-treatment FDG-PET to prognosticate patients and determine likelihood of response to treatment however they are still not used commonly. This article was a review of the literature available on pre-treatment FDG PET quantitative parameters and their value in predicting failure. A thorough review of literature from MEDLINE and EMBASE was performed on pre treatment quantitative parameters in HNSCC. Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) were reliable parameters to predict response to organ preservation therapy, disease free and overall survival. SUVmax was an inconsistent parameter. MTV and TLG may help predict poor response to organ preservation to initiate early surgical salvage or modify therapeutic decisions to optimize clinical outcomes. Routine incorporation into PET reporting may provide additional information over SUVmax alone.

Narayana Subramaniam, Deepak Balasubramanian*, Shanmuga Sundaram P and Samskruthi Murthy 


Article Image 1

Staged Surgery Combined with Chemo Radiation Improves Outcome after Incomplete Removal of Gallbladder Cancer

Introduction: Gallbladder carcinoma is the most frequent tumor of the bile system and has a poor prognosis. The main proportion of tumors diagnosed coincidentally after gallbladder removal for various reasons. In these cases, an incomplete removal of the tumors occurs frequently. The adequate treatment of these patients is still under discussion. We present our experience with different procedures.

Patients and Methods: Between 1990 and 2015, we identified 20 patients which were presented at our University Hospital after incomplete removal of gallbladder cancer (R1, R2, RX) as incidental findings after cholecystectomy. The prospectively collected data including surgery, adjuvant treatment, histopathological examinations of the specimens and follow-up data were analyzed retrospectively.

Results: The median age of patients was 72 years (range 47-89 years), 90 % (18/20) were female. The median follow-up period was 10 months (range 0-109 months). The median survival of all patients was 11 months (95 % confidence interval: 5-17 months). The median survival of patients who received staged surgery and chemo radiation after incomplete gallbladder removal was significantly increased (median 32 months; range 4-109 months) vs. patients who received chemo radiation without surgery (median 13 months; range 8-51 months) or chemotherapy alone (median 2.5 months (range 0-40 months)) (p = 0.005).

Discussion: There is no standardized treatment for residual tumor after incomplete gallbladder cancer resection. Our data demonstrate that staged surgery with prior chemo radiation may improve patient´s outcome. Surgery can be performed with low morbidity and mortality.

Marc Daniels¹, Maximilian Brunner¹, Sabine Semrau², Robert Grützmann¹ and Roland S Croner¹*


Article Image 1

Limb Salvage in Patients with Unresectable Recurrent Melanoma and Sarcoma with the Hyperthermic Isolated Limb Perfusion Technique

Introduction: Hyperthermic Isolated Limb Perfusion (HILP) is a surgical procedure for the regional delivery of heat and high doses of chemotherapy and biologic agents to the extremity. The procedure is employed as a limb salvage technique for locally advanced primary malignancies or recurrent cancers that are unresectable and confined to the extremity

Methods: From 1987-2016, 247 patients with unresectable recurrent melanoma (95%), sarcoma or Merkel Cell Carcinoma underwent HILP for limb salvage of the affected extremity after staging was negative for Stage IV disease and disease was confirmed to be confined to the extremity.

Results: All patients had limb salvage with this protocol. All patients were clinically negative in their regional basin at the time of perfusion, although 40% of the patients had evidence of regional nodal disease following nodal dissections. Immediate responses (within 3 months) on the extremity to the HILP were as follows: complete response (CR) of 66%, partial response (PR) of 20%, 10% stable disease and 4% progressive disease. With a mean follow-up period of 5 years, 61.5% of the patients have recurred with 68.4% of the recurrences being systemic, 21% regional nodal, 7.2% in-transit and 3.3% local-regional soft tissue.

Conclusions: HILP is an effective strategy for limb salvage in patients with unresectable, locally advanced cancers confined to the extremity. The treatment was associated with a high rate of complete responses on the extremity. Most patients recurred with distant metastases emphasizing the need for better systemic therapies for these malignancies.

Synopsis: Patients with recurrent, unresectable melanoma, other cutaneous malignancies and sarcoma confined to an extremity are problematic for clinicians since recurrence rates show that most will have occult systemic disease. An aggressive amputation approach does not make sense and the fact that these patients have active disease makes them ineligible for approved adjuvant therapies. In addition since their clinically apparent active disease is confined to the local/regional soft tissues making them Stage 3 disease, they are not eligible for Stage IV protocols. In these situations Hyperthermic Isolated Limb Perfusion (HILP) effectively treats the extremity with high response rates and a 100% limb salvage rate.

Lauren Kerivan, Michael Reintgen, Eric Reintgen, Steve Shivers and Douglas Reintgen* 


Article Image 1

Self-related Quality of Life and Functional Results after Internal and External Hemipelvectomy in 82 Musculoskeletal Pelvic Tumours

Background and purpose: Wide resection in pelvis delivers important drawbacks not only physically but also mentally lowering the functional status and self-related quality of life (SRQL) of these patients. Our aim is to show functional results and SRQL in patients with wide resections in pelvis due to musculoskeletal tumours.

Patients and Methods: It is a retrospective study in patients with wide resections in pelvis due to musculoskeletal tumours and we focus on: demographical data, preoperative and pathology studies, type of resection and reconstruction, functional results (MSTS score) and SRQL (SF-12). We have performed 15 external hemipelvectomies (EH), 57 internal hemipelvectomies with pelvic ring stability reconstruction (IHPR), 10 internal hemipelvectomies without reconstruction of the pelvic stability (IHWR). There were 10 patients with soft tissue sarcomas and benign but aggressive tumours that we do not include in the study as they did not need hemipelvectomy.

Results: We found there is a tendency to better functional results in IHPR, though it shows no statistical differences between the three types of reconstruction. According to SRQL we observed light score loss in mental status related to general population. On the other hand, physical status showed strong score deviation from general population. Functional results seem to be similar to literature.

Interpretation: The severe loss of function and physical status in these patients underline the type reconstruction and avoiding complications as critical steps. The light score deviation in mental status may represent an adaptive pattern and social support of patients with this severe disease and its complications.

Pérez-Muñoz Israel*


Article Image 1

Alveolar Soft Part Sarcoma: Case Report of a Rare Tumor and Review of Literature

Alveolar soft part sarcoma (ASPS) is a rare neoplasm occurring most frequently in the soft tissues of both children and adults, which has a tendency for an indolent course and late metastasis. It is characterized by an unbalanced translocation, der(17)t(X:17)(p11;p25), producing a fusion protein which has recently been shown to play a role in promoting cell proliferation and angiogenesis and may provide a potential target for molecular therapy. We present a case of ASPS and discuss the histology, diagnostic considerations, cytogenetics, treatment, and prognosis.

Glyn Hinnenkamp*, Amy Hackett, Brandon Grodman, Logan Primeaux , Ashley Green, Savannah Sadaiappen , Sylvester Bote, and Mohamed Aziz 


Article Image 1

Secondary primary common bile duct neuroendocrine tumor 10 years after the diagnosis of rectal adenocarcinoma: A case report

Development of a second primary cancer in patients under follow-up because of metastasis is rare. We presented a 58-year-old man with neuroendocrine cancer of vater ampulla and distal common bile duct as a second primary cancer. The patient had been diagnosed with rectal adenocarcinoma and lung metastasis who underwent total mesorectal excision, lung lobectomy, and adjuvant therapy with an interval of 5 years. This article emphasizes on the importance of early detection of second primary cancer and treating it as the primary one

Saba Ebrahimian MD, Sakineh Soleimani Varaki MD